

Another milestone: *Stem Cell Investigation* is indexed in PubMed/PMC

Skylar Gao

Editorial Office, Stem Cell Investigation, Guangzhou 510220, China

Correspondence to: Skylar Gao, Science Editor, Editorial Office, Stem Cell Investigation, AME Publishing Company, Room 807, Jinhui Building, No. 123, Jiefang Road, Yuexiu District, Guangzhou 510000, China. Email: editor@sci-online.org.

Received: 26 April 2016; Accepted: 27 April 2016; Published: 28 April 2016.

doi: 10.21037/sci.2016.04.04

View this article at: <http://dx.doi.org/10.21037/sci.2016.04.04>

On April 25, 2016, an expected and exciting news from the PubMed Central was emailed to the Editorial Office: the *Stem Cell Investigation* (SCI) has passed all the evaluation required by PubMed Central (PMC) and is officially accepted for inclusion in PubMed/PMC—an extensive and important biomedical online journal repository! Successful coverage in the prestigious PubMed database not only means the recognition of *SCI* by international peers, but, more importantly, is another milestone for *SCI* to move towards the master publication list of SCI-indexed journals.

All previously published content on *SCI* will be searchable within 1–2 months. Consequently, authors publishing in *SCI* will enjoy maximum exposure of their research. The inclusion in this prominent database convincingly demonstrates the high quality of the published work and the journal's significant potential. Thus, *SCI* would like to express our sincere appreciation for the enthusiastic and vigorous support and contributions from all board members, reviewers, authors, and readers.

Launched in February 2014, *Stem Cell Investigation* (SCI; ISSN 2306-9759) is a free access, peer-reviewed online journal covering basic, translational, and clinical research on all aspects of stem cells. Most of its articles are original research articles and reviews on embryonic stem cells, induced pluripotent stem cells, adult tissue-specific stem/progenitor cells, cancer stem like cells, stem cell niche, stem cell technology, stem cell based drug discovery, and regenerative medicine (Figure 1).

Another distinguished features of *SCI* lies on its fast-track publication—all articles could go online quickly once accepted in *SCI* without delay in fitting the publication frequency, thus keeping the newest finding and researches




Figure 1 Article type of *SCI* (data updated on April 26, 2016).

on stem cell online.

SCI's Publisher: AME Publishing Company

AME Publishing Company (www.amegroups.com) is an international publisher of medical books and journals, who now owns more than 20 journals covering different fields of medicine including oncology, pulmonology, cardiothoracic disease and urology. Each journal features peer-reviewed original contributions, comprehensive reviews, and editorials, as well as current case reports etc. AME Publishing Company have an integrated publishing system featuring a professional and highly efficient editorial team, to ensure that every part of our work from sending invitation to online publication goes as close-knit as following the assemble line, needless to say the robust electronic dissemination system for all our journals and articles. Currently, AME has 17 sister journals indexed by PubMed (PMC or Medline) and 6 journals

indexed in Web of Science (SCIE or ESCI): specifically, 2 journals indexed by SCIE (*Journal of Thoracic Disease* and *Translational Cancer Research*), and 4 journals indexed by Emerging Sources Citation Index (ESCI)/WOS (*Annals of Cardiothoracic Surgery*, *Journal of Gastrointestinal Oncology*, *Cardiovascular Diagnosis and Therapy*, and *Translational Gastrointestinal Cancer*).

doi: 10.21037/sci.2016.04.04

Cite this article as: Gao S. Another milestone: *Stem Cell Investigation* is indexed in PubMed/PMC. *Stem Cell Investig* 2016;3:14.

Acknowledgements

None.

Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.